Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Nature - 15 Apr 2012

Smith Catherine C, Wang Qi, Chin Chen-Shan, Salerno Sara, Damon Lauren E, Levis Mark J, Perl Alexander E, Travers Kevin J, Wang Susana, Hunt Jeremy P, Zarrinkar Patrick P, Schadt Eric E, Kasarskis Andrew, Kuriyan John, Shah Neil P

Abstract excerpt

Effective targeted cancer therapeutic development depends upon distinguishing disease-associated 'driver' mutations, which have causative roles in malignancy pathogenesis, from 'passenger' mutations, which are dispensable for cancer initiation and maintenance. Translational studies of clinically active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzothiazoles
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Molecular Structure

Share to Molecular Targeted Therapy

Share to Phenylurea Compounds

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 22504184
DOI: 10.1038/nature11016
PMCID: PMC3390926

Genes

FLT3
KIT
PDGFRA
PDGFRB
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.PMID 22504184Read ↗

Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Semantic proximity Read ↗

The FLT3 tyrosine kinase receptor ITD mutation controls its expression and drug resistance in acute myeloid leukaemiaSemantic proximity Read ↗

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.Semantic proximity Read ↗

Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736Semantic proximity Read ↗

Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.Semantic proximity Read ↗

Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.Semantic proximity Read ↗

The role of quizartinib in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

The Future of Targeting FLT3 Activation in AML.Semantic proximity Read ↗

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.Semantic proximity Read ↗

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.Semantic proximity Read ↗

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.